Overall Survival and Treatment Patterns Among Patients With Warm Autoimmune Hemolytic Anemia in Sweden: A Nationwide Population‐based Study
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14311 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Honar Cherif und 7 weiteren Autor:innen. Beteiligte Einrichtung: Uppsala University Hospital, Uppsala, Sweden. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Autoimmune, Registries. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Global Services, LLC, Johnson & Johnson Innovative Medicine.
Abstract (Originalsprache)
Objectives
Warm autoimmune hemolytic anemia (wAIHA) is a rare autoantibody‐mediated disorder, and first‐line treatment primarily relies on corticosteroids. This study assessed overall survival (OS) and treatment patterns of wAIHA in Sweden.
Methods
Adults with ≥ 1 primary diagnosis code for wAIHA (or AIHA plus oral corticosteroids (OCS)/immunosuppressants as sensitivity analyses) between 2011 and 2022 were identified from five Swedish national registers and linked through each patient's unique identity number. Kaplan–Meier curves with log‐rank tests and Cox regressions were performed to assess OS for patients with primary versus secondary wAIHA and patients with wAIHA and long‐term versus short‐term (≥ 3 vs. < 3 months) OCS users.
Results
The main analysis included 292 patients; 1791 patients were included in the sensitivity analysis. At a median 3.7‐year follow‐up, a median OS in primary wAIHA was not reached versus 6.0 years for secondary wAIHA (log‐rank test: p = 0.003). Subgroup analyses showed no significant difference in risk of death between long‐term and short‐term OCS users; however, in the sensitivity analysis, long‐term OCS users showed significantly higher risk of death (adjusted hazard ratio: 1.45; 95% confidence interval: 1.180, 1.781; p < 0.001) versus short‐term OCS users.
Conclusion
Secondary wAIHA or long‐term OCS use was associated with lower OS, underscoring the disease burden and unmet need for efficacious wAIHA treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Uppsala University Hospital, Uppsala, Sweden.
- Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, New Jersey, USA.
- Janssen Global Services, LLC, a Johnson & Johnson Company, Horsham, Pennsylvania, USA.
- SDS Life Science-A Cytel Company, Stockholm, Sweden.
- Janssen Pharmaceutica NV, Solna, Sweden.
- Janssen Pharmaceutica NV, Brussels, Belgium.
ORCID-Profile: Honar Cherif
Förderung
- Janssen Global Services, LLC
- Johnson & Johnson Innovative Medicine
Zitieren
APA
Cherif, H., Cai, Q., Crivera, C., Leon, A., Rahman, I., Leval, A., Noel, W., & Kjellander, C. (2025). Overall Survival and Treatment Patterns Among Patients With Warm Autoimmune Hemolytic Anemia in Sweden: A Nationwide Population‐based Study. European Journal of Haematology. https://doi.org/10.1111/ejh.14311
Vancouver
Cherif H, Cai Q, Crivera C, Leon A, Rahman I, Leval A, et al. Overall Survival and Treatment Patterns Among Patients With Warm Autoimmune Hemolytic Anemia in Sweden: A Nationwide Population‐based Study. European Journal of Haematology. 2025. doi:10.1111/ejh.14311
BibTeX
@article{Cherif2025,
author = {Cherif, Honar and Cai, Qian and Crivera, Concetta and Leon, Ann and Rahman, Iffat and Leval, Amy and Noel, Wim and Kjellander, Christian},
title = {Overall Survival and Treatment Patterns Among Patients With Warm Autoimmune Hemolytic Anemia in Sweden: A Nationwide Population‐based Study},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14311}
}
EUVIMED